AbbVie 8-K

Summary

AbbVie debt issuance. AbbVie agreed to sell $8.0B of senior notes across seven tranches, with closing expected on 3/4/2026 subject to customary conditions. Net proceeds are intended to repay amounts outstanding under a term loan facility and for general corporate purposes, including possible repayment or repurchase of debt.

Key Figures

• Principal: $750M floating-rate notes due 2028; fixed-rate notes of $1.5B at 3.775% due 2028, $1.25B at 4.125% due 2031, $1.25B at 4.400% due 2033, $1.5B at 4.750% due 2036, $1.25B at 5.550% due 2056, and $500M at 5.650% due 2066.
• Public offering prices as a percentage of principal: 100.000% for floating-rate notes; 99.966% for 2028, 99.972% for 2031, 99.861% for 2033, 99.911% for 2036, 99.736% for 2056 and 99.714% for 2066 notes.
• Net proceeds expected: ≈$7.95B. AbbVie plans to repay its $2.0B currently outstanding under a $4.0B 364-day delayed-draw term loan facility maturing in May 2026; remaining proceeds are for general corporate purposes, potentially including repayment or repurchase of debt.
• The underwriting agreement is with J.P. Morgan Securities, BofA Securities, Morgan Stanley and Wells Fargo, acting as representatives of the underwriters.

Investor Takeaways

• Watch for completion of the sale on 3/4/2026 and the planned repayment of the outstanding term-loan balance.